Circulating miRNAs in Hypertrophic Cardiomyopathy: A Long and Bumpy Road

HomeCirculation: Heart FailureVol. 16, No. 6Circulating miRNAs in Hypertrophic Cardiomyopathy: A Long and Bumpy Road No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextCirculating miRNAs in Hypertrophic Cardiomyopathy: A Long and Bumpy Road Peter van der Meer and Sophie Van Linthout Peter van der MeerPeter van der Meer Peter van der Meer, MD, PhD, Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands, Email E-mail Address: [email protected] https://orcid.org/0000-0002-9705-4413 Department of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands (P.v.d.M.). Search for more papers by this author and Sophie Van LinthoutSophie Van Linthout Correspondence to: Sophie Van Linthout, PhD, Berlin Institute of Health Center for Regenerative Therapies, Föhrerstrasse 15, 13353 Berlin, Germany, Email E-mail Address: [email protected] https://orcid.org/0000-0002-7581-7870 Berlin Institute of Health (BIH) at Charité, BIH Center for Regenerative Therapies, Germany (S.V.L.). German Center for Cardiovascular Research (DZHK), partner site Berlin, Germany (S.V.L.). Search for more papers by this author Originally published12 Jun 2023https://doi.org/10.1161/CIRCHEARTFAILURE.123.010694Circulation: Heart Failure. 2023;16This article is a commentary on the followingCirculating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic CardiomyopathyComprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling PathwaysFootnotesFor Sources of Funding and Disclosures, see pages 541 and 542.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Sophie Van Linthout, PhD, Berlin Institute of Health Center for Regenerative Therapies, Föhrerstrasse 15, 13353 Berlin, Germany, Email sophie.van-linthout@bih-charite.dePeter van der Meer, MD, PhD, Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands, Email p.van.der.meer@umcg.nlReferences1. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.J Am Coll Cardiol. 2014; 64:83–99. doi: 10.1016/j.jacc.2014.05.003CrossrefMedlineGoogle Scholar2. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.Circ Res. 2017; 121:749–770. doi: 10.1161/CIRCRESAHA.117.311059LinkGoogle Scholar3. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2020; 76:e159–e240. doi: 10.1016/j.jacc.2020.08.045CrossrefMedlineGoogle Scholar4. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).Circulation. 2018; 138:1387–1398. doi: 10.1161/CIRCULATIONAHA.117.033200LinkGoogle Scholar5. Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy.Eur J Heart Fail. 2016; 18:457–468. doi: 10.1002/ejhf.495CrossrefMedlineGoogle Scholar6. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression.Proc Natl Acad Sci U S A. 2006; 103:2746–2751. doi: 10.1073/pnas.0511045103CrossrefMedlineGoogle Scholar7. Sucharov C, Neltner B, Pietra AE, Karimpour-Fand A, Patel J, Ho CY, Miyamoto SD. Circulating microRNA identify early phenotypic changes in sarcomeric hypertrophic cardiomyopathy.Circ Heart Fail. 2023; 16:526–539. doi: 10.1161/CIRCHEARTFAILURE.122.010010LinkGoogle Scholar8. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, Cirino AL, Lakdawala NK, Orav EJ, Gonzalez A, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.Circ Cardiovasc Imaging. 2013; 6:415–422. doi: 10.1161/CIRCIMAGING.112.000333LinkGoogle Scholar9. Liang LW, Hasegawa K, Maurer MS, Reilly MP, Fifer M, Shimada YJ. Comprehensive transciptomics profiling of microRNA reveals plasma circulating biomarkes of hypertrophic cardiomyopathy and dysregulated signaling pathways.Circ Heart Fail. 2023; 16:515–525. doi: 10.1161/CIRCHEARTFAILURE.122.010010LinkGoogle Scholar10. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy.Circ Res. 1998; 83:594–601. doi: 10.1161/01.res.83.6.594LinkGoogle Scholar11. Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.Nat Rev Cardiol. 2021; 18:169–193. doi: 10.1038/s41569-020-00435-x.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCirculating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic CardiomyopathyCarmen C. Sucharov, et al. Circulation: Heart Failure. 2023;16Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling PathwaysLusha W. Liang, et al. Circulation: Heart Failure. 2023;16 June 2023Vol 16, Issue 6 Advertisement Article Information Metrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.123.010694PMID: 37306007 Originally publishedJune 12, 2023 KeywordsEditorialscardiomyopathydiagnosisgenotypemiRNAnucleotidesarcomeretranscriptomePDF download Advertisement Subjects Biomarkers Cardiomyopathy Hypertrophy